Advertisement
Home American Society of Hematology 2020

American Society of Hematology 2020

Vaccination healthcare concept. Hands of doctor or nurse in medical gloves injecting a shot of vaccine to a man patient

Subcutaneous Daratumumab Regimen Improves PFS in Pre-Treated Myeloma

Data presented at the ASH 2020 Annual Meeting & Exhibition showed that subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) significantly reduced risk of disease...

CELMoD Combinations Effective in Treating Relapsed/Refractory Multiple Myeloma

Iberdomide, an oral potent novel cereblon E3 ligase modulator (CELMoD), in combination with other agents demonstrated an acceptable toxicity profile and promising clinical activity...

Multiple Myeloma Clinical Trial Selection Bias Impacts Real-World Efficacy of Treatments

A study presented at the ASH Annual Meeting & Exposition found that among six landmark multiple myeloma (MM) clinical trials, the ineligibility rates were...

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group...

Despite improved outcomes with current MM treatments, most patients (pts) will develop refractory disease, highlighting the need for novel treatments. GPRC5D is an orphan...

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific...

Background: MM inevitably relapses and becomes refractory to treatment, representing a patient (pt) population with unmet needs. Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3...

177 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen...

Background: Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells) is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen–targeting single-domain antibodies designed to confer...

Results from the Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients...

Background: B-cell maturation antigen (BCMA) is widely expressed on normal plasma cells and malignant plasma cells in multiple myeloma (MM). MEDI2228 is an antibody-drug conjugate...
Advertisement
Advertisement